Rebuilding Limbs, Rethinking Care: A Q&A with Orthofix’s Patrick Fisher

Orthopedic device maker Orthofix was founded in 1980 in Verona, Italy, by orthopedic researcher Giovanni De Bastani and his colleagues. The company was established to develop and market external fixation devices based on the concept of “dynamization” for bone healing. Its first limb lengthener debited in 1981, followed by the Limb Reconstruction System in 1987. Orthofix became listed on Nasdaq as OFIX in 1992.

In its more than four decades in business, the company has evolved and grown to become one of the world’s leading medical device companies, with a focus on spine and limb reconstruction. Orthofix is headquartered in Lewisville, Texas, and offers a portfolio spanning spinal implants, therapeutic solutions, limb reconstruction systems, biologics, and enabling technologies like the 7D FLASH navigation system.

ODT editorial board member Patrick Fisher joined Orthofix’s executive leadership team in 2024 as president of Global Limb Reconstruction, and broadened his scope in 2026 to include overseeing the company’s Biologics business.

Before Orthofix, Fisher served as the vice president and general manager of Stryker Corporation’s Foot and Ankle business. Before his tenure at Stryker, he was president of Lower Extremity and Biologics for Wright Medical Technology, which was acquired by Stryker in 2020. Fisher joined Wright Medical in 2002 and held multiple positions of increasing responsibility, including vice president of U.S. sales.

He also serves on several boards, including CurveBeam AI as an independent non-executive director, the University of Tennessee Research Advisory Board, and the Mission 3A Healthcare Advisory Board. ODT spoke to Fisher to hear his unique voice on the orthopedic device industry.

Sam Brusco: What inspires you most about your work in limb reconstruction and biologics? 

Patrick Fisher: What inspires me most is seeing the profound impact we can have on patients’ lives. Many patients—or parents of young patients—come to us after consulting with 10-12 surgeons who felt their condition was too complex to treat. Limb length discrepancies and deformity corrections are among the most challenging procedures in orthopedics, and witnessing successful outcomes after years of pain, uncertainty, and limited options is incredibly motivating.

Brusco: What macro trends (e.g., aging population, value-based care) are influencing strategy in limb reconstruction? 

Fisher: Orthofix is defining a new orthopedic category built around four pillars: Limb Lengthening, Deformity Correction, Limb Preservation, and Complex Fracture Management. The most significant macro trend shaping this category is rising patient demand, fueled by greater patient education and awareness. Many individuals who were once told “nothing can be done” are now learning—often via social media and surgeon‑led educational channels—that solutions do exist. Surgeon communities such as the LLRS (Limb Lengthening and Reconstruction Society) and similar global groups are amplifying this awareness. The aging population and rapid advancements in technology also play a major role. Breakthrough solutions like Fitbone Nails and the TrueLok Elevate System simply did not exist a few years ago, demonstrating the accelerating pace at which innovation is expanding treatment possibilities.

Brusco: How is the landscape shifting in terms of reimbursement and regulatory expectations for biologics? 

Fisher: Payers are increasingly requiring medical device manufacturers to demonstrate that premium‑priced products deliver measurable value, supported by strong clinical or pre‑clinical evidence. On the reimbursement side, bone graft substitutes—whether DBM, CBM, or synthetics—typically do not receive a separate add‑on payment. They are treated as components of the overall procedure payment, and this structure has remained largely unchanged in recent years. Regulatory bodies are also moving toward more stringent quality expectations and more rigorous evidence requirements for performance claims.

Brusco: What unmet clinical needs in biologics and limb re- construction do you believe have the greatest opportunity for breakthrough solutions? 

Fisher: In limb reconstruction, limb preservation represents the most significant unmet need and the largest opportunity for breakthrough innovation. As diabetes‑related complications continue to rise, more patients are at risk of amputation—yet the morbidity data for these patients is poor. Developing stronger limb preservation solutions is, therefore, a core focus of our team. In biologics, we see opportunities in small‑molecule alternatives and next‑generation synthetic biologics, both of which could meaningfully reshape clinical practice.

Brusco: How do you see Orthofix differentiating itself from competitors in the biologics and reconstruction market? 

Fisher: Orthofix Biologics has a long history of innovation and strong market penetration. Most hardware companies achieve about a 20% biologics pull‑through rate, but our biologics utilization relative to hardware sales is significantly higher, highlighting our deeper integration and broader clinical adoption. Our multi‑brand strategy enables us to offer industry‑leading DBM, cellular allograft, and synthetic solutions. Historically we have focused our biologics efforts on the spine market, and expanding beyond spine represents an important growth lever. In Limb Reconstruction, Orthofix stands apart as the only company solely dedicated to this segment of the $65 billion orthopedic market. This singular focus allows us to direct R&D, marketing, sales, and medical education efforts with exceptional precision. Surgeons worldwide have responded positively to the creation of this dedicated, clearly defined category.

Brusco: What was the rationale behind changing Orthofix’ s focus to limb reconstruction? 

Fisher: When I first joined Orthofix, one of our first priorities was to refine and clarify our brand identity. We were previously described in many different ways—Foot & Ankle, Extremity, Pediatric, Trauma, External Fixation—which diluted our strategic direction. In reevaluating who we truly are, Limb Reconstruction emerged as the unifying theme. Our expertise in Limb Lengthening, Deformity Correction, Limb Preservation, and Complex Fracture Management aligned naturally under this new category, helping surgeons and hospital partners better understand who we are and what we uniquely provide.

Brusco: What is your vision for the Global Biologics and Limb Reconstruction businesses over the next 3-5 years? 

Fisher: Our goal in Limb Reconstruction is to fully define and lead this new market category. We aim to become the #1 company for limb reconstruction procedures and the surgeons who perform them—driving growth by investment in R&D, clinical evidence, marketing, and surgeon and patient education. 

In Biologics, our vision is to strengthen and expand our market share leadership position through a portfolio anchored in our deep biologics heritage, in‑house manufacturing expertise, our development partnership with MTF (the most recognized tissue bank in the field), and a focus on market‑differentiated products across all key biologics segments. Together, these efforts position us to advance meaningful innovation and deliver life-changing solutions for patients and providers worldwide.